
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
IPI-145 and ABT-199 for Lymphoid Malignancies
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Advertisement
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Learn more about inhibiting BCL-2 > >
Articles in this issue
over 11 years ago
In the Pipeline: Potential New Treatments for AMLover 11 years ago
Epidemiology in B-Cell Malignanciesover 11 years ago
Pathogenesis of Follicular Lymphomaover 11 years ago
Resistance to Ibrutinibover 11 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































